Showing posts with label maternal immune activation (MIA). Show all posts
Showing posts with label maternal immune activation (MIA). Show all posts

Saturday, 4 November 2017

Maternal immune history and autism (social) symptom severity

"Pregnant mothers' asthma and allergies linked to more severe autism in their children" went one of the media headlines discussing the findings reported by Patel and colleagues [1]. Drawing on data derived from the "Western Australian Autism Biological Registry (WAABR)" researchers set out to examine whether "having an immune or autoimmune-driven MIA [maternal immune activation] is associated with increased severity of ASD [autism spectrum disorder] symptoms for the child."

The conclusions arrived at: "a positive immune history (allergies or asthma) was associated with increased severity of social symptoms in child." Said data derived from 220 families/children who were quizzed about "the medical history of the biological mother, where details regarding any diagnosed illnesses or chronic conditions were reported, along with age of any diagnosis" alongside the use of more direct measures to ascertain autistic traits in children: Autism Diagnostic Observation Schedule-Generic (ADOS-G) and the Social Responsiveness Scale (SRS).

One obviously has to be a little cautious about such results where the study was conducted 'retrospectively' and what this could mean in terms of recall [2] (although, I hasten to add, other studies of maternal recall vs. medical records in the context of autism are actually quite promising). That no objective confirmation of the presence of allergy or autoimmune disease via direct testing for example, were included in this publication is also something to be a little careful about (I'm pretty sure however, someone would know if they had received a diagnosis of coeliac disease or not for example).

So what do the results mean and what are the implications? Well, MIA - maternal immune activation - in the context of offspring autism risk is not something new (see here and see here for examples) as the authors mention in their paper. Added to work talking about how inflammation, a process that is part-and-parcel of immune function, might have the ability to 'affect' social cognitive processing (see here) one might see further evidence for how the immune system seems to be doing quite a bit more than just protecting us from the odd pathogen or two. This might be particularly relevant during pregnancy; a time when a reprogrammed immune system is in place to prevent mum's body from 'rejecting' the developing foetus and associated systems.

"Findings support the role of an immune system-mediated subtype in ASD, which may be driven by MIA and changes in levels immune markers. Identification of such a subtype in ASD will enable more streamlined diagnosis and management in clinical environments." Yes, alongside acknowledgement that there may be an 'immune phenotype' of autism (see here), the authors do mention the potential future use of "immune-modulating pharmacotherapies" in the context of the growing evidence base for MIA and risk of offspring autism. Such options are already being explored in the animal research domain as per those findings from Vuillermot and colleagues [3] and how "early dietary supplementation with vitamin D may open new avenues for a successful attenuation or even prevention of neurodevelopmental disorders following maternal inflammation during pregnancy." Vitamin D and autism is already quite a hot topic (see here for example). And things don't just stop at vitamin D neither (see here for another example) as further investigations are warranted with the hope that children with possible 'MIA autism' (if I can use that term) are "able to function and integrate into the world... [and] have a level of independence" required to do so successfully (and of course, happily).

----------

[1] Patel S. et al. Social impairments in autism spectrum disorder are related to maternal immune history profile. Molecular Psychiatry. 2017. Oct 10.

[2] Ozonoff S. et al. Reliability of parent recall of symptom onset and timing in autism spectrum disorder. Autism. 2017 Sep 1:1362361317710798.

[3] Vuillermot S. et al. Vitamin D treatment during pregnancy prevents autism-related phenotypes in a mouse model of maternal immune activation. Mol Autism. 2017 Mar 7;8:9.

----------

Monday, 31 July 2017

Placental inflammation and autism?

The placenta. Quite an important part of the nine months that makes us; an organ exquisitely evolved to provide oxygen and nutrition to the developing embryo/foetus as well as removing various un-necessaries. Without it we wouldn't even be...

A recent paper by Jennifer Straughen and colleagues [1] suggests that when it comes to the placenta and it's important functions during gestation, there may be some interesting data pertinent to at least some cases of autism spectrum disorder (ASD). Indeed the authors note: "Histologic evidence of placental inflammation and maternal vascular malperfusion pathology are associated with ASD."

Based on identifying some 55 persons diagnosed with ASD and nearly 200 matched controls, researchers analysed findings based on placentas "reviewed as part of routine care." Although not particularly au-fait with the inner workings of the placenta, I understand that various 'issues' were screened for and some interesting observations made. Words like 'acute placental inflammation' and 'maternal vascular malperfusion pathology' are banded around; many of which seemed to be more frequently associated with a subsequent diagnosis of ASD. In short, there seemed to be quite a bit more going on with those placentas from mums of children with autism compared with the not-autism controls.

This is important work. I've talked about the placenta and offspring autism previously a few times on this blog (see here and see here for examples). Allied to the rather sweeping idea that autism 'begins in-utero' and there is a case to be made for further inspection of organs like the placenta [2] when it comes to at least some cases of offspring autism - some, but not all. Indeed, it is perhaps timely that other independent papers [3] remind us of the work of the late Paul Patterson et al and the concept of maternal immune activation (MIA) and how the required reprogramming of the maternal immune system during pregnancy might very much rely on optimal placental function to keep the developing child safe and sound...

----------

[1] Straughen JK. et al. The association between placental histopathology and autism spectrum disorder. Placenta. 2017. July 8.

[2] Schroeder DI. et al. Placental methylome analysis from a prospective autism study. Mol Autism. 2016 Dec 15;7:51.

[3] Bilbo SD. et al. Beyond infection - Maternal immune activation by environmental factors, microglial development, and relevance for autism spectrum disorders. Experimental Neurology. 2017. July 8.

----------

Tuesday, 27 June 2017

MoBa does prenatal fever and autism risk

'MoBa does..' is fast becoming a common title on this blog (see here and see here). Referring to the Norwegian Mother and Child Cohort Study (MoBa), this initiative based on the examination of 100,000 pregnancies in Norway is yielding some useful observations for all-manner of different condition/labels.

When MoBa is applied to autism, a few names seem to quite consistently crop up - Mady Hornig and Ian 'virus hunter' Lipkin - as is the same for today's blogging material from Hornig and colleagues [1] (open-access). Their findings supporting "a role for gestational maternal infection and innate immune responses to infection in the pathogenesis of at least some cases of ASD [autism spectrum disorder]" make for interesting reading.

Authors set about determining whether maternal fever episodes during pregnancy might show some connection with risk of offspring autism. To do this they relied on questionnaire data from pregnant mums completed at specific times of their pregnancy pertinent to "fever, along with their timing, as well as the names of medications used for fever, and the timing of that medication use" as a function of a subsequent diagnosis of offspring autism or not. That 'medication use' side of things adds to a further stream of research suggesting that some medicines used as fever-reducers/eliminators (antipyretics) during pregnancy might also have some bearing on offspring behavioural/developmental outcomes (see here and see here for examples). Alongside such information, authors also took into account various potentially confounding variables that might have also affected offspring autism risk.

Results: based on data covering nearly 100,000 children, with nearly 600 subsequently being diagnosed with an ASD, researchers concluded that: "Prenatal fever was associated with increased ASD risk among offspring." Exposure to reported pregnancy fever at any time during pregnancy seemed to be more common in those children who were eventually diagnosed with ASD but notably during the second trimester of pregnancy. They also noted a possible dose-response effect from pregnancy fever exposure: "Risks increased markedly and dose dependently with fever frequency, with particularly strong effects after 12 weeks’ gestation." As to the use of antipyretics and any additional risk or mitigation of risk, I'm inclined to suggest that on this research occasion, there wasn't very much to see either way.

Added to the idea that infection exposure during the nine months that makes us might also affect the risk of subsequent offspring autism (see here), this latest data sit well with the idea that infection and/or response to infection during pregnancy might very well be able to influence offspring outcomes. Pregnancy is a time of reprogrammed maternal immune function (to stop mum's immune system attacking the developing foetus) so already science has a basis for looking at something like enhanced maternal immune activation (MIA) during pregnancy as being potentially pertinent to offspring outcomes particularly autism.

Of course one has to note that the strengths of the MoBa study - "a large, prospective, population-based birth cohort with exposure data collected in 4-week intervals and linkage to a patient registry for case ascertainment" - need to be balanced against the weakness, i.e. maternal self-report. The authors have however promised more detailed study in this area: "we are testing the possibility that risk is associated with specific infectious agents through sequence-based and serological assays of samples collected mid-pregnancy and at birth from cases and controls" so there may be more to add in future times [2] in addition to some already published inklings from authors (see here).

----------

[1] Hornig M. et al. Prenatal fever and autism risk. Molecular Psychiatry. 2017. June 13.

[2] Mahic M. et al. Epidemiological and Serological Investigation into the Role of Gestational Maternal Influenza Virus Infection and Autism Spectrum Disorders. mSphere. 2017. June 21.

----------

Friday, 28 April 2017

Autism, pregnancy maternal immune activation and vitamin D?

Today's post is a bit of a mash-up, drawing on two articles quite recently published in the peer-reviewed science domain.

The first is by Stephanie Vuillermot and colleagues [1] (open-access) suggesting that "early dietary supplementation with vitamin D may open new avenues for a successful attenuation or even prevention of neurodevelopmental disorders following maternal inflammation during pregnancy." These findings have also received some media attention (see here for example) and continues a research theme focused on vitamin D (the sunshine vitamin/hormone) and [some] autism (see here for example).

The second paper is by Michael Lombardo and colleagues [2] (open-access) and also covers the topic of maternal immune activation (MIA) and its potential effects on offspring outcomes, concluding that: "MIA may confer increased risk for ASD [autism spectrum disorder] by dysregulating key aspects of fetal brain gene expression that are highly relevant to pathophysiology affecting ASD."

What are the connections between these papers? Well, obviously both deal with the concept of maternal immune activation (MIA) where infection, or possibly/rather 'inflammatory' responses to infection, during critical periods of pregnancy seem to be able to affect offspring developmental and other outcomes. This bearing in mind that pregnancy represents a time of 'reprogrammed immune function' such that the maternal immune system does not mount a response to the genetically dissimilar organism growing inside the body. Both papers model MIA in rodents (mice and rats respectively) given the ethics of undertaking such experimental studies in humans. Both studies concluded that (a) there is evidence that MIA is a real phenomenon and (b) bearing in mind rodents are not necessarily the same as humans (see here) (a shocker I know), MIA seems to invoke specific biochemical changes pertinent to the expression of genes *linked* to autism that are also potentially amenable to intervention.

The Vuillermot findings in particular, offer some rather intriguing prospects for further study as a function of their conclusion that: "maternal VitD co-administration blocked the emergence of the ASD-relevant deficits in social interaction, stereotyped behavior, and emotional learning and memory." I appreciate that 'blocking the emergence' of autistic behaviours is not something that everyone is going to unanimously welcome (the implication being that every single autistic trait is somehow something to be eradicated). The idea however that aspects of even something like certain stereotyped behaviours under certain conditions and with certain intensity might 'set someone up' for the presentation of truly disabling conditions such as anxiety [3] (see here too) offers a degree of support for the idea of intervention targeting such behaviours in particular circumstances.

But there is a potential research spanner in the works when it comes the idea that vitamin D might 'offset' some of the changes associated with exposure to MIA. The authors note: "VitD does not alter maternal or fetal inflammatory cytokine production." This statement was made on the basis that "prenatal administration of vitamin D had no effect on pro-inflammatory cytokine levels in dams or in fetal brains." Cytokines are those chemical messengers of the immune system. How then, you might ask? Well, back to the Lombardo paper and the possibility that vitamin D is not necessarily an 'anti-inflammatory' of choice under such circumstances but might - MIGHT - act on some of the mechanisms related to those genes expressed under MIA conditions. It's pretty well-known for example, that vitamin D does influence gene expression (see here for example) as our knowledge of the biological duties of the sunshine vitamin/hormone expand (see here). It is logical to assume that the next research step would be to see whether vitamin D administration *might* at certain times and under certain circumstances, affect the expression of those genes 'highly relevant to pathophysiology affecting ASD' under MIA conditions. This, in the context that maternal vitamin D levels during pregnancy again *might* have an important impact on the presentation of offspring autistic traits (see here).

And since we're on the topic of vitamin D and autism (yet again), how about reading a new hypothesis paper on some potentially important connections [4]?

----------

[1] Vuillermot S. et al. Vitamin D treatment during pregnancy prevents autism-related phenotypes in a mouse model of maternal immune activation. Molecular Autism. 2017; 8: 9.

[2] Lombardo MV. et al. Maternal immune activation dysregulation of the fetal brain transcriptome and relevance to the pathophysiology of autism spectrum disorder. Mol Psychiatr. 2017. Mar 21.

[3] Bitsika V. & Sharpley CF. The association between parents' ratings of ASD symptoms and anxiety in a sample of high-functioning boys and adolescents with Autism Spectrum Disorder. Res Dev Disabil. 2017 Mar 1;63:38-45.

[4] Gillberg C. et al. The role of cholesterol metabolism and various steroid abnormalities in autism spectrum disorders: A hypothesis paper. Autism Res. 2017. April 12.

----------

ResearchBlogging.org Vuillermot, S., Luan, W., Meyer, U., & Eyles, D. (2017). Vitamin D treatment during pregnancy prevents autism-related phenotypes in a mouse model of maternal immune activation Molecular Autism, 8 (1) DOI: 10.1186/s13229-017-0125-0




ResearchBlogging.org Lombardo, M., Moon, H., Su, J., Palmer, T., Courchesne, E., & Pramparo, T. (2017). Maternal immune activation dysregulation of the fetal brain transcriptome and relevance to the pathophysiology of autism spectrum disorder Molecular Psychiatry DOI: 10.1038/mp.2017.15

Saturday, 18 March 2017

HSV-2 gestational infection and offspring autism risk

"In our cohort, high levels of antibodies to herpes simplex virus 2 at midpregnancy were associated with an elevated risk of autism spectrum disorder in male offspring. These findings provide support for the hypothesis that gestational infection may contribute to the pathogenesis of autism spectrum disorder and have the potential to drive new efforts to monitor women more closely for cryptic gestational infection and to implement suppressive therapy during pregnancy."

That was the conclusion reached in the paper published by Milada Mahic and colleagues [1] including the research tag-team that is Mady Hornig and Ian 'virus hunter' Lipkin in the list of contributing authors. Having already received some media attention (see here), it doesn't need much more from me but I do want to include a few details and relevant points in this blog entry.

So, the Autism Birth Cohort was the starting point, and "442 mothers of children with ASD... and 464 frequency-matched controls" who all provided plasma samples "(903 samples acquired at midpregnancy and 878 acquired after delivery)." Said samples were analysed for IgG antibodies to ToRCH agents: "Toxoplasma gondii, rubella virus, cytomegalovirus (CMV), and herpes simplex viruses 1 (HSV-1) and 2 (HSV-2)." Some of those viruses and parasites have previously been mentioned with [some] autism in mind (see here and see here and see here).

Results: well, an important detail first: "Because rubella vaccination is part of the routine child vaccination schedule in Norway, almost all individuals had IgG antibodies to rubella virus." Indeed, other authors have speculated that rubella vaccination has actually "prevented substantial numbers" of autism as a knock-on effect of reducing the numbers of cases of congenital rubella syndrome [2]. Vaccination doing more than just saving lives eh?

Next: "Our data suggest that the presence of high levels of anti-HSV-2 antibodies at midpregnancy increases the risk of ASD [autism spectrum disorder] in boys." The authors complemented this finding by some rather neat statistical wizardry whereby odds ratios were calculated based on "four different anti-HSV-2 reference levels (60, 120, 180, and 240 arbitrary units [AU]/ml)." Having said that: "High levels of antibodies, which are typically indicative of recent infection, were found in only a small number of subjects." They also reported "no statistically significant association with risk was found with high levels of HSV-2 antibodies at delivery" and saw nothing significant when it came to the other infections examined. These important points have been picked up in the NHS Choices entry on this study (see here).

These are interesting findings and, as far as I can see, represent something quite novel to the quite vast autism research landscape (assuming you count maternal HSV-2 levels and not antibody levels in actual people diagnosed with autism). The reliance on data from an initiative like the Autism Birth Cohort ensured some rigour in terms of the diagnosis of autism [3] and with the reputations following Drs Hornig and Lipkin, one would have to be pretty brave to question their virus-hunting credentials also with autism in mind [4].

Then to the million-dollar question: how might elevated HSV-2 antibodies during pregnancy affect offspring risk of autism? There is a familiar theme offered by the authors to this question as per statements like: "ASD risk associated with high levels of antibodies to HSV-2 is not specific to HSV-2 but instead reflects the impact of immune activation and inflammation on a vulnerable developing nervous system." I know some people still have a bit of a problem with the idea that something like maternal immune activation (MIA) might up the risk for various offspring outcomes [hint: if an article contains the word 'truth' in the title, step away] but please, stop with the 'it can never happen' generalisations and instead look to the existing peer-reviewed evidence on the topic [5]. Yes, science needs to do more on the topic of MIA and autism but clues are emerging all the time...

Oh, and I'll be coming to research talking about another member of the herpesviruses in relation to autism quite soon on this blog.

To close, operation hardtack and other videos (best viewed in full-screen mode).

----------

[1] Mahic M. et al. Maternal Immunoreactivity to Herpes Simplex Virus 2 and Risk of Autism Spectrum Disorder in Male Offspring. mSphere. 2017. Feb 22.

[2] Berger BE. et al. Congenital rubella syndrome and autism spectrum disorder prevented by rubella vaccination - United States, 2001-2010. BMC Public Health. 2011; 11: 340.

[3] Stoltenberg C. et al. The Autism Birth Cohort (ABC): A Paradigm For Gene-Environment-Timing Research. Molecular Psychiatry. 2010;15(7):676-680.

[4] Hornig M. et al. Lack of association between measles virus vaccine and autism with enteropathy: a case-control study. PLoS One. 2008 Sep 4;3(9):e3140.

[5] Careaga M. et al.  Maternal Immune Activation and Autism Spectrum Disorder: From Rodents to Nonhuman and Human Primates. Biol Psychiatry. 2017 Mar 1;81(5):391-401.

----------

ResearchBlogging.org Milada Mahic, Siri Mjaaland, Hege Marie Bøvelstad, Nina Gunnes, Ezra Susser, Michaeline Bresnahan, Anne-Siri Øyen, Bruce Levin, Xiaoyu Che, Deborah Hirtz, Ted Reichborn-Kjennerud, Synnve Schjølberg, Christine Roth, Per Magnus, Camilla Stoltenberg, Pål Surén, Mady Hornig, & W. Ian Lipkin (2017). Maternal Immunoreactivity to Herpes Simplex Virus 2 and Risk of Autism Spectrum Disorder in Male Offspring. mSphere : 10.1128/mSphere.00016-17

Saturday, 17 December 2016

Pregnancy influenza infection not linked to offspring autism

"There was no association between maternal influenza [flu] infection anytime during pregnancy and increased ASD [autism spectrum disorder] risk."

So said the findings reported by Ousseny Zerbo and colleagues [1] continuing a research theme from this author (see here for example) looking at how various infections 'encountered' during critical periods of pregnancy may / may not impact on offspring autism risk. This time around the focus was on viral infections and in particular "maternal influenza infection and vaccination from conception date to delivery date" as derived from either diagnosis using ICD-9 criteria or "a positive laboratory result for influenza based on the Prodesse ProFlu+ Assay (Hologic), a multiplex real-time polymerase chain reaction in vitro diagnostic test." Said participants numbering nearly 200,000 children were all born "at Kaiser Permanente Northern California from January 1, 2000 to December 31, 2010, at a gestational age of at least 24 weeks." The press release accompanying the publication can be seen here.

"Maternal influenza infection during pregnancy was not associated with increased ASD risk in this study, and the association did not vary by the timing of influenza infection." Importantly, authors also looked at whether maternal influenza vaccination during pregnancy was also related to offspring ASD risk based on the data contained in their patient databases. The results pertinent to pregnancy flu vaccination and offspring risk were not exactly cut-and-dried as "in an initial analysis unadjusted for multiple comparisons" the authors reported seeing a 'slightly increased' risk for offspring autism associated with maternal vaccination during the first few months of pregnancy. This was set against data indicating no significant association between maternal influenza vaccination covering 'anytime' during pregnancy. Indeed, after "adjusting for the multiplicity of hypotheses tested" they concluded that the first trimester vaccination - offspring autism risk was potentially a 'chance finding'. Minus any scaremongering and to be on the safe side the authors suggested that "additional studies are warranted to further evaluate any potential associations between first-trimester maternal influenza vaccination and autism."

Aside from a few potential 'weakness' attached to the Zerbo results including the fact that "subclinical infections or illnesses for which women did not seek medical attention" were not counted in the data, these are interesting results. Quite a few times on this blog I've covered the so-called maternal immune activation (MIA) hypothesis - where mum's reprogrammed pregnancy immune system is 'challenged' and potentially has implications for offspring development - and this work kinda falls into that category of autism science. Indeed, I've talked about the possibility quite recently (see here). Drawing also on data looking at season of conception/birth as potentially being important to pregnancy viral/bacterial exposure and onward offspring outcomes (see here) there has been a steady stream of peer-reviewed publications hinting at a potentially important 'association' between infection exposure in-utero and developmental outcomes for the child. The current Zerbo data however put a bit of a research spanner in the works when it comes specifically to any pregnancy flu and offspring autism risk suggestion albeit with the continued requirement for further investigations in this area covering other infections.

----------

[1] Zerbo O. et al. Association Between Influenza Infection and Vaccination During Pregnancy and Risk of Autism Spectrum Disorder. JAMA Pediatr. 2016 Nov 28.

----------

ResearchBlogging.org Zerbo O, Qian Y, Yoshida C, Fireman BH, Klein NP, & Croen LA (2016). Association Between Influenza Infection and Vaccination During Pregnancy and Risk of Autism Spectrum Disorder. JAMA pediatrics PMID: 27893896

Monday, 12 December 2016

Maternal immune activation (MIA) and Old World monkeys

Old World monkeys detailed in the title of this post, specifically refers to a type of animal called a rhesus macaque who were the 'participants' of choice as detailed in a recent study by Destanie Rose and colleagues [1] looking at a concept called maternal immune activation (MIA).

Those who followed this blog down the years will no doubt have seen me discuss MIA before in the context of autism and/or schizophrenia (see here for example). The basic theory is that whilst in-utero and enjoying approximately nine months in a warm and comfortable environment with a reprogrammed maternal immune system to stop a mother's body from 'rejecting' a developing foetus, infections encountered by the mother at critical periods of pregnancy might themselves or through their effects on the maternal immune system, have the ability to 'affect' offspring outcomes in a variety of ways. The majority of work on the concept of MIA has been in smaller animals such as rodents, so the inclusion of rhesus macaques is an important step as it was in other work with the immune system and autism in mind (see here).

So, take 21 pregnancy rhesus macaques and give them either "three injections over 72 hours of poly I:C-LC [an immune stimulant], a double stranded RNA analog (viral mimic), or saline as a control." Said injections were given either "near the end of the first trimester or near the end of the second trimester" to see whether timing of immune stimulation might be important. Macaque offspring were subsequently born and followed for about 4 years. Blood samples were collected from offspring "at the end of their first (year 1) and fourth (year 4) years to assess dynamic cellular immune function." At the same time, the behaviours of monkey offspring were also analysed to see if there were any effects from MIA exposure.

Results: behaviour did seem to be affected by MIA exposure, particularly stereotyped behaviours, noted to be a core feature of autism. Similarly, researchers reported some important immune system 'changes' associated with MIA exposure: "elevated production of innate inflammatory cytokines including: interleukin (IL)-1β, IL-6, IL-12p40, and tumor necrosis factor (TNF)α" at 1 year of age. Immune system changes were also noted longer-term at 4-years: "the MIA exposed offspring continued to display elevated IL-1β, and there was also a pattern of an increased production of T-cell helper type (TH)-2 cytokines, IL-4 and IL-13." Although being careful not to generalise too much when it comes to immune system markers and what they mean for pro- or anti-inflammatory signals, the leaning towards the production of Th-2 cytokines is typically linked to atopy and 'the promotion of IgE and eosinophilic responses in atopy.' The authors - including some notable names from the MIND Institute - conclude by suggesting that: "Data from this study suggests long-term behavioral and immune activation was present in offspring following MIA."

Accepting that animal models of something like MIA are not necessarily the same as human MIA and its responses, this is interesting work. If one however accepts the data on something like vaccine function being modelled in animals (see here for example) is akin to what happens in people, real people, there is some added strength to the information published by Rose and other groups on how MIA may indeed be a relevant factor when it comes to immune function potentially affecting offspring behaviour and development.

This research also intersects with quite a lot of other peer-reviewed science talking about how (human) pregnancy infection does seem to be related to offspring risk for conditions such as autism (see here). That various immune-related conditions such as asthma in mothers might also 'prime' for offspring neurodevelopmental issues is another important strand of research potentially pertinent to this area (see here). And then also there is the idea of an 'inflammatory autism subtype' (see here) also previously suggested continuing the important theme of immune function and behaviour/development being linked. There are, as you can see, quite a few potentially important connections that can be made between the Rose results and other data on MIA and offspring development.

Oh, and I'll be coming to the recent paper by Zerbo and colleagues all in good time...

----------

[1] Rose DR. et al. Long-term altered immune responses following fetal priming in a non-human primate model of maternal immune activation. Brain Behav Immun. 2016 Nov 19. pii: S0889-1591(16)30522-0.

----------

ResearchBlogging.org Rose, D., Careaga, M., Van de Water, J., McAllister, K., Bauman, M., & Ashwood, P. (2016). Long-term altered immune responses following fetal priming in a non-human primate model of maternal immune activation Brain, Behavior, and Immunity DOI: 10.1016/j.bbi.2016.11.020

Monday, 11 July 2016

Expanding MAR autism

MAR autism - maternal autoantibody-related autism - is a term that has graced this blog before (see here). Describing a state where autoantibodies directed against foetal brain proteins have been detected in some mothers who have children diagnosed with an autism spectrum disorder (ASD), the suggestion is that such evidence further substantiates a role for various maternal immune functions and processes when it comes to offspring risk of at least some types of autism.

Although interesting, the research road travelled by MAR autism has not been a smooth one (see here). Indeed one of the outstanding questions has been whether the detection of such autoantibodies is more or less likely when various other conditions affecting the mother might be present (see here) and perhaps synergistically elevating the risk of offspring autism. The paper by Paula Krakowiak and colleagues [1] further explored this question and concluded that: "mothers whose children had severe ASD and who experienced diabetes were more likely to have anti-fetal brain autoantibodies 2–5 years later."

Some media about the Krakowiak study can be seen here. Based on participants - "227 mothers of 2–5 year old children with confirmed ASD" - all enrolled in CHARGE (be in CHARGE!) researchers set about looking at whether "ASD-specific maternal autoantibodies identified postnatally were associated with metabolic conditions (MCs) during gestation." Said metabolic conditions (MCs) included "diabetes, hypertensive disorders, and prepregnancy obesity or overweight, ascertained from medical records or structured telephone interviews." Indeed Paula Krakowiak has some research history with MCs in mind (see here) that has subsequently been replicated in other cohorts (see here).

Results: well, aside from a quarter of mothers presenting with those autoantibodies (based on the analysis of archived blood samples) authors reported that: "Ab+ [anti-fetal brain autoantibodies positive] prevalence was higher among mothers with diabetes, hypertensive disorders, or overweight compared to healthy mothers, but differences were not statistically significant." What this means is that overall there was a trend towards elevated risk of Ab+ in  those mothers with various metabolic conditions but this might have just been a chance finding. Unfortunately some of the media reports on this specific point are found wanting...

When it came however to looking at those mothers who had children who "exhibited severe ASD" they suggested that those diagnosed with type-2 diabetes or gestational diabetes "were 2.7-fold more likely to be Ab+." Further: "Gestational diabetes specifically was associated with a 3.2-fold increased Ab+ prevalence."

As per some of the media interest in these results there are a few [cautious] 'take-away messages' from the findings. The idea for example, that the presence of certain metabolic conditions "may alter the maternal immune tolerance to the fetus during pregnancy" is an important one in the context of words like 'inflammation' being potentially involved (see here for another example of this). I would however like to see a little more science done on the specific biology of how obesity might bring about autoantibodies with autism specifically in mind based on other findings [2].

That preferential screening of the offspring of those mothers diagnosed with a metabolic condition either before or during pregnancy might be offered is another message bearing in mind how stretched screening and diagnostic services seem to be in many parts of the world. The idea also that where and when 'severe ASD' is reported, further research investigations might focus in further on this topic and how findings might manifest in the children with ASD themselves is also deserving of attention.

Oh, and then there is the further evidence afforded to the term 'the autisms' by the Krakowiak results...

----------

[1] Krakowiak P. et al. Autism-specific maternal anti-fetal brain autoantibodies are associated with metabolic conditions. Autism Research. 2016. June 17.

[2] Arai S. et al. Obesity-associated autoantibody production requires AIM to retain the immunoglobulin M immune complex on follicular dendritic cells. Cell Rep. 2013 Apr 25;3(4):1187-98.

----------

ResearchBlogging.org Krakowiak P, Walker CK, Tancredi D, Hertz-Picciotto I, & Van de Water J (2016). Autism-specific maternal anti-fetal brain autoantibodies are associated with metabolic conditions. Autism research : official journal of the International Society for Autism Research PMID: 27312731

Friday, 15 April 2016

The transgenerational effects of prenatal immune activation?

The paper by Ulrike Weber-Stadlbauer and colleagues [1] provides some food for thought today with the suggestion that the concept of prenatal immune activation might have consequences further than just to exposed offspring.

For those not familiar with the concept of prenatal immune activation, it refers to the process(es) that occur following "exposure to infectious or inflammatory insults" during the nine months that made us. As you'll probably be aware, our nine months of watery 'captivity' is an important time in making us who we are. It is also a time when we are unfortunately vulnerable to quite a few factors that can adversely affect our stay in the womb (see here and see here for examples) and indeed, that can have repercussions for our future development and wellbeing. Among the vast number of agents that can and do affect pregnancy, various infectious agents (such as viruses and bacteria) that have been with humankind since the year dot play a prominent role; either through their own actions or via what biochemical processes they initiate as a mother's body seeks to protect itself and its unborn child. In short, the maternal immune system might itself, at this crucial time of reprogrammed immune tolerance, exert a less than positive effect on the foetus as a result. The sorts of outcomes potentially linked to exposure to this prenatal immune activation are varied to say the least (see here).

Weber-Stadbauer et al looking at a mouse model of prenatal immune activation - that's MOUSE model - took things one stage further by asking whether effects of such immune activation exposure might persist beyond just one generation of offspring. So: "Using an established mouse model of prenatal immune activation by the viral mimetic poly(I:C), we show that reduced sociability and increased cued fear expression are similarly present in the first- and second-generation offspring of immune-challenged ancestors." Further: "These transgenerational effects are mediated via the paternal lineage and are stable until the third generation, demonstrating transgenerational non-genetic inheritance of pathological traits following in-utero immune activation."

When the authors suggest that their results "demonstrates for, we believe, the first time that prenatal immune activation can negatively affect brain and behavioral functions in multiple generations" they aren't kidding. Indeed, accompanied by the rise and rise of research talking about transgenerational inheritance not primarily mediated by more traditional structural genetics (as far as we know) the possibilities are truly endless if said processes are indeed transferable from mouse to humans.

But just before we do get too carried away, let's be a little cautious. Aside from the fact that mice are mice and not humans (see here) and that complex behaviours like human sociability are probably not best served by looking solely at mice, these data need to be independently replicated. I note from other research by members of this authorship group [volumes of research it has to be said] the interest in how a label like 'schizophrenia' (or should that be schizophrenias?) might have a 'developmental neuroinflammation' element to it [2] implies that priming of the immune system should be something that is detectable (see here) and hence potentially amenable to change. Indeed, this may very well tie into the increasingly popular idea that immunopsychiatry is here to stay (see here). I would therefore, like to see a little more on how prenatal immune activation presents in immune system terms down the generations over and above "unique and overlapping genome-wide transcriptional changes in first- and second-generation offspring of immune-challenged ancestors." Does, for example, this imply that there is a potential biomarker set consisting of biochemical, epigenetic and transcriptional data that might characterise those at risk of such consequences? And indeed, are we all potentially the result of our grandmother's immune experiences as we might be her dietary patterns?

To close, following the sad news that Gareth 'Blake's 7' Thomas has died, that theme tune...

----------

[1] Weber-Stadlbauer U. et al. Transgenerational transmission and modification of pathological traits induced by prenatal immune activation. Mol Psychiatry. 2016 Mar 29.

[2] Meyer U. Developmental neuroinflammation and schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2013; 42: 20-34.

----------

ResearchBlogging.org Weber-Stadlbauer U, Richetto J, Labouesse MA, Bohacek J, Mansuy IM, & Meyer U (2016). Transgenerational transmission and modification of pathological traits induced by prenatal immune activation. Molecular psychiatry PMID: 27021823

Monday, 1 February 2016

On (pre)pregnancy obesity and inflammation and offspring autism risk

At the time of writing this [long read] post there has been a flurry of autism research articles making news.

The headline: 'Scientists create the first ever autistic monkeys' referring to the work published by Liu and colleagues [1] who reported on "lentivirus-based transgenic cynomolgus monkeys (Macaca fascicularis) expressing human MeCP2 in the brain exhibit autism-like behaviours and show germline transmission of the transgene" started the ball rolling. Anyone who knows a little bit about autism will realise that mutations in the MeCP2 gene generally refers to Rett syndrome. Whilst linked to the expression of certain autistic-like behaviours, Rett syndrome is but one part of the very heterogeneous spectrum called autism. I'd also suggest that other primate research had previously 'modelled' autism, or at least, certain facets of autism (see here).

Next up was the headline: 'Autism Diets: Can Nutrition Have An Impact On Autism Risk?' portraying the findings reported by Xie and colleagues [2] (open-access) who talked about inborn errors of carnitine metabolism potentially being linked to some autism. This follows some important research history in this area (see here) specifically linked to a gene called trimethyllysine hydroxylase, epsilon (TMLHE) (see here). Inborn errors of metabolism potentially linked to autism (some autism) is a woefully under-researched and under-screened area (see here).

And then we have two papers that make up the core of today's post. The first by Mengying Li and colleagues [3] continues something of an important theme in autism research circles these days on how mum's weight and risk of diabetes during pregnancy might have a bearing on offspring development [4], and specifically the risk of autism and comorbid learning disability. This time around researchers "examined the independent and combined effects of maternal prepregnancy obesity and maternal diabetes on the risk of autism spectrum disorder (ASD) in parallel with other developmental disorders (DDs)." They did this by analysing data - "a subset of the Boston Birth Cohort who completed at least 1 postnatal study visit at Boston Medical Center between 1998 and 2014" - and comparing rates of autism ("based on physician diagnoses as documented in electronic medical records") and other diagnoses "among 6 groups defined by maternal prepregnancy obesity and diabetes status." They found that yes, those mums who were obese and presented with pregestational diabetes (PGDM) had a [significantly] increased risk of offspring autism as were those with both obesity and gestational diabetes. Interestingly: "This pattern of risk was mostly accounted for by cases with co-occurring ASD and ID."

Before heading further into the potential whys and wherefores to account for the Li results, I want to bring in another paper making news. Gloria Choi and colleagues [5] report results that have created headlines such as: 'Autism caused by immune response to viral infection during pregnancy?' Accepting that again, the use of the singular term 'autism' in that media piece does little to accentuate the degree of diversity that the label includes and the various 'routes' that might bring someone to a diagnosis (see here for example), I found this to be an interesting paper.

Building on the idea that viral infection during pregnancy might be able to affect offspring risk of autism or other behavioural outcomes (see here), researchers set about looking at some of the possible mechanisms involved in this process. The work of the late Paul Patterson (see here) gets a mention in the Choi study write-up and the concept of maternal immune activation (MIA). Pregnant mice were initially artificially 'immune stimulated' and offspring were found to display the sorts of behaviours that had previously been mentioned in the science literature in this area. Researchers then took out some key elements of the cells involved in the inflammatory response to immune activation - specifically Th17 cells - and repeated the artificial immune activation procedure. Offspring mice did not appear to show the same behavioural issues as those whose mother mice possessed their Th17 cells intact. Further, when pregnant mother mice were given an antibody that blocks interleukin-17 (IL-17) (produced by Th17 cells), offspring mice also showed behavioural differences compared with those offspring whose mother mice received immune stimulation but nothing else. Ergo, the suggestion that: "therapeutic targeting of TH17 cells in susceptible pregnant mothers may reduce the likelihood of bearing children with inflammation-induced ASD-like phenotypes." The idea of an 'inflammation-induced autism phenotype' by the way is not a new one (see here).

Whilst remembering that mice are mice (and monkeys are monkeys) and so not necessarily able to model all of the complexity of human autism (and its important comorbidities), these are potentially important findings. I've covered the idea that immune function and inflammatory processes might be part and parcel of some autism previously on this blog (see here for example) as part of a larger shift in psychiatry circles (see here). Indeed, some of that research has specifically talked about IL-17 and at least some autism (see here for example) and the idea that levels might be increased compared to other groups. Insofar as the notion of blocking the effects of IL-17 (or Th17), I'm minded to suggest that we need a lot more data first before specific interventions are discussed or attempted including looking at compounds linked to the maturation of Th17 cells [6] as possible targets.

What the Li and Choi papers share in common are several variables. First is the idea that 'the nine months that made us' might indeed be an important time insofar as future behavioural outcome. Indeed the Li results also suggest that what happens prepregnancy might also exert a significant effect. Second is the notion that inflammation (or response to inflammation) in-utero might be an important concept for at least some 'types' of autism and indeed other future diagnoses (see here). If you're wondering what obesity might have to do with inflammation, well, let's just say that quite a few researchers/research groups believe there is an important link [7] and certainly some write-up on the Li paper makes that point. I say this acknowledging that Li and colleagues also noted the children with autism in their cohort were also more likely to be born preterm and with a low birth weight. Finally, is the question of whether disrupting inflammatory processes or responses particularly during critical times of prepregnancy and/or pregnancy might be something to look at with a view to altering any 'programmed' offspring autism or other risk. Appreciating that not everyone might receive this question the same way, I do think we need to have some frank discussions about this option. That Li and colleagues reported on prepregnancy obesity/diabetes as being particularly associated with autism and learning (intellectual) disability perhaps provides an important detail pertinent to the idea of improving child outcomes and quality of life (particularly if pregnancy inflammation translates into offspring inflammation and where that could lead).

Some important future research directions are indicated.

Music, and what else but Terry Wogan and The Floral Dance. Rest in peace Sir Terry and not forgetting your best quotes...

----------

[1] Liu Z. et al. Autism-like behaviours and germline transmission in transgenic monkeys overexpressing MeCP2. Nature. 2016 Jan 25.

[2] Xie Z. et al. Inborn Errors of Long-Chain Fatty Acid β-Oxidation Link Neural Stem Cell Self-Renewal to Autism. Cell Reports. 2016. Jan 28.

[3] Li M. et al.  The Association of Maternal Obesity and Diabetes With Autism and Other Developmental Disabilities. Pediatrics. 2016. Jan 29.

[4] Connolly N. et al. Maternal metabolic risk factors for autism spectrum disorder-An analysis of electronic medical records and linked birth data. Autism Res. 2016 Jan 29.

[5] Choi GB. et al. The maternal interleukin-17a pathway in mice promotes autism like phenotypes in offspring. Science. 2016. 28 Jan.

[6] Huang W. et al. DDX5 and its associated lncRNA Rmrp modulate TH17 cell effector functions. Nature. 2015 Dec 24;528(7583):517-22.

[7] Lumeng CN. & Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011 Jun;121(6):2111-7.

----------

ResearchBlogging.org Li, M., Fallin, M., Riley, A., Landa, R., Walker, S., Silverstein, M., Caruso, D., Pearson, C., Kiang, S., Dahm, J., Hong, X., Wang, G., Wang, M., Zuckerman, B., & Wang, X. (2016). The Association of Maternal Obesity and Diabetes With Autism and Other Developmental Disabilities PEDIATRICS, 137 (2), 1-10 DOI: 10.1542/peds.2015-2206



ResearchBlogging.org Choi GB, Yim YS, Wong H, Kim S, Kim H, Kim SV, Hoeffer CA, Littman DR, & Huh JR (2016). The maternal interleukin-17a pathway in mice promotes autismlike phenotypes in offspring. Science (New York, N.Y.) PMID: 26822608

Wednesday, 4 February 2015

A rat model of early immune stimulation

It took me a few a reads of the paper by Anna Kubesova and colleagues [1] (open-access) to understand just how potentially important their findings might be to various conditions including schizophrenia and autism.

Reporting results of a study where "early immune stimulation induced by postnatal systemic administration of LPS [lipopolysaccharide]" was performed in rats, researchers examined various potential effects on "the levels of monoamines (dopamine, serotonin) and their metabolites, and the levels of the main excitatory and inhibitory neurotransmitters glutamate and γ-aminobutyric acid (GABA) in the brain" and "activation of the kynurenine pathway of tryptophan metabolism." Brain morphology, and in particular, hippocampal volume was also the topic of some investigation.

Before coming to the results, a few additional points are worthwhile mentioning. Rats were the participants of choice in this study. I say again, rats were the participants of choice. The use of the word 'postnatal' to denote how LPS - one of the artificial immune activation weapons of choice - was administered after birth was also of initial interest to me, given that prenatal immune activation (that is immune stimulation administered to pregnant mother mice/rats/monkeys and then analysis of the effects on offspring after birth conducted) has been where the majority of the research has been done in this area (see here). The authors do comment on this however: "The early postnatal period in rats corresponds approximately with the third trimester of human brain development" although the difference between injecting LPS into offspring rats vs. pregnant rats is still present. LPS was also administered via intraperitoneal injection, that is the into the peritoneum, the tissue that lines the abdominal wall.

OK, so what did they find? Well, quite a bit, for example:

  • Analysis of neurotransmitters and metabolites in brain and plasma of LPS treated and control rats were carried out by "liquid chromatography combined with electrospray ionization tandem mass spectrometry (UHPLC–ESI-MS/MS)" based on methods reported in a previous study [2]. Curiously however, authors chose to present a HPLC trace (Figure 1) showing the separation of the analytes over and above the more superior mass spec results. I would have preferred to have seen those any day.
  • The authors reported: "significantly increased levels of DOPAC [3,4-dihydroxyphenylacetic acid], HVA [homovanilic acid] and 5-HIAA [5-hydroxyindolacetic acid] and decreased levels of 5-HT [serotonin] and 3-MT [3-methoxytyramine] in each measured brain area in LPS treated animals compared with the control group."
  • Further: "There were significantly increased levels of GLU [glutamate] in each measured brain area, decreased levels of GABA in the hippocampus and a decreasing trend of GABA in the prefrontal cortex in LPS treated animals compared with the control group."
  • And also: "We detected significantly increased levels of TRP [tryptophan], KYN [kynurenine], 3-OH-KYN [3-hydroxykynurenine] and QUIN [quinolinic acid] in each measured brain area and plasma in LPS treated animals compared with the control group."
  • Differences in brain morphology are also reported as per the finding: "early postnatal LPS administration led to a volume reduction of the hippocampus."

And with all that, again bearing in mind that this was a study of rats, the authors conclude that: "Our results suggest a pathogenetic link between early immune stimulation and neuropsychiatric disorders such and schizophrenia, mood disorders, anxiety disorders, autism, Parkinson’s disease and Alzheimer’s disease."

These are interesting results that require both replication and follow-up. Of all the findings presented as potentially being connected to early immune stimulation, I was particularly interested in those related to kynurenine and some previous work talking about a kynurenic acid hypothesis of schizophrenia (see here). Kubesova and colleagues do talk about their results not necessarily fitting in with the idea that elevated kynurenic acid (KYNA) might be linked to at least some cases of schizophrenia [3] as per the fact that they: "did not find any change of KYNA levels in the brain or plasma compared to the controls." Activation of this pathway and a link with those dastardly pro-inflammatory cytokines (see here) (which were surprisingly not measured in the current study) might however offer some important clues on how immune activation links into some of the metabolites of little 'ole tryptophan and where future work might go from there.

The findings of elevated levels of tryptophan in both plasma and brain of LPS treated animals and reduced levels of tyrosine hydroxylase positive cells in certain parts of the brain was also something which got me thinking. Tyrosine hydroxylase as one of the triad of aromatic amino acid hydroxylases (metabolising tryptophan, tyrosine and phenylalanine) is a valued user of something called tetrahydrobiopterin (BH4), a substrate which has been mentioned a few times on the blog with autism (see here), schizophrenia (see here) and more classically, phenylketonuria (PKU) (see here) in mind. Aside from the potential effect of immune activation on levels of tyrosine hydroxylase bearing in mind how this family of enzymes might not necessarily be too exclusive in what they metabolise [4], I'm wondering whether BH4 might be something else to look at in future work given it's already known-about link to immune activation [5] alongside say, levels of tryptophan hydroxylase too? Indeed, the fact also that higher levels of tryptophan were noted in LPS treated animals but lower levels of 5-HT (serotonin) in "each measured brain area" could be construed as offering further support for closer inspection of tryptophan enzyme chemistry in this immune related model.

I know animal studies such as this one have to be cautiously interpreted in terms of how well they extend to complex labels such as autism or schizophrenia, with their very wide degree of heterogeneity and important mix of comorbidities. This still doesn't stop me however from being really quite interested in where the Kubesova findings might eventually lead us. I might also link you to the paper from Luan and colleagues [6] and another area crying out for further study with maternal immune activation in mind...

Music: Nick Cave & The Bad Seeds with Red Right Hand.

----------

[1] Kubesolva A. et al. Biochemical, Histopathological and Morphological Profiling of a Rat Model of Early Immune Stimulation: Relation to Psychopathology. PLoS ONE. 2015; 10(1): e0115439.

[2] Najmanová V. et al. LC-ESI-MS-MS Method for Monitoring Dopamine, Serotonin and Their Metabolites in Brain Tissue. Chromatographia. 2011; 73: 143-149.

[3] Erhardt S. et al. The kynurenic acid hypothesis of schizophrenia. Physiol Behav. 2007 Sep 10;92(1-2):203-9.

[4] Roberts KM. & Fitzpatrick PF. Mechanisms of Tryptophan and Tyrosine Hydroxylase. IUBMB Life. 2013.; 65: 350–357.

[5] Neurauter G. et al. Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr Drug Metab. 2008 Sep;9(7):622-7.

[6] Luan R. et al. Maternal Lipopolysaccharide Exposure Promotes Immunological Functional Changes in Adult Offspring CD4+ T Cells. Am J Reprod Immunol. 2015 Jan 30.

----------

ResearchBlogging.org Kubesova A, Tejkalova H, Syslova K, Kacer P, Vondrousova J, Tyls F, Fujakova M, Palenicek T, & Horacek J (2015). Biochemical, Histopathological and Morphological Profiling of a Rat Model of Early Immune Stimulation: Relation to Psychopathology. PloS one, 10 (1) PMID: 25602957

Saturday, 31 January 2015

Suramin and the Fragile X (Fmr1 knockout) mouse model (and autism)

Fancy some weekend reading? Well, you could do a lot worse than having a gander through the paper by Jane Naviaux and colleagues [1] (open-access) discussing the results of a whole host of analyses following the use of the antipurinergic agent suramin on a mouse model of Fragile X syndrome.
Overprotective mother, forbidden road trip...

Regular readers might remember some previous discussions about suramin - a pharmaceutic designed to treat African sleeping sickness - and autism which have graced this blog (see here and see here). Following a series of studies which looked at the physiological and behavioural effects of suramin administration on a mouse model trying to recreate conditions of maternal immune activation (MIA (which itself has some autism research history), authors this time turned their attention to a mouse model of Fragile X syndrome, a condition which can in humans manifest with autistic traits (sometimes).

The Naviaux paper is a whopper in terms of data accumulated and results so I'm not going to even try and summarise the findings aside from quoting the authors that their: "results support the novel conclusion that antipurinergic therapy is operating by a mechanism that lies close to the root cause of the core behaviors and development in both the environmental MIA, and the genetic Fragile X models of ASD [autism spectrum disorder]. This mechanism appears to be traceable to mitochondria and regulated by purinergic signaling." Both mitochondrial and purinergic issues have featured in the autism research historical tapestry before (see here and see here respectively).

Just before anyone makes a run on suramin, I might however point out a few things: (a) the current and previous results are based on mouse studies and mice are mice not humans, and (b) suramin, whilst indicated for sleeping sickness, is not without the possibility of some pretty important side-effects (see here).

Still, this latest paper again potentially opens up a number of promising lines of inquiry in need of further investigation. And the added bonus is to see some more metabolomics included in their results!

To close: INXS and Mystify.

----------

[1] Naviaux JC. et al. Antipurinergic therapy corrects the autism-like features in the fragile X (Fmr1 knockout) mouse model. Molecular Autism 2015, 6:1

----------

ResearchBlogging.org Jane C Naviaux, Lin Wang, Kefeng Li, A Taylor Bright, William A Alaynick, Kenneth R Williams, Susan B Powell, & Robert K Naviaux (2015). Antipurinergic therapy corrects the autism-like features in the fragile X (Fmr1 knockout) mouse model Molecular Autism : 1186/2040-2392-6-1